Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3 years versus 5 years of adjuvant imatinib for high-risk GIST
ACTRN12621001756819Phase 3Active, not recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Recurrence-free survival. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ACTRN12621001756819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001756819.